The State Key Laboratory of Oncology in Southern China

Guangzhou, China

The State Key Laboratory of Oncology in Southern China

Guangzhou, China
SEARCH FILTERS
Time filter
Source Type

Gao Y.,Methodist Hospital Research Institute | Gao Y.,Baylor College of Medicine | Gao Y.,key Medical Center | Gao Y.,The State Key Laboratory of Oncology in Southern China | And 30 more authors.
Radiation Oncology | Year: 2011

Background: Perifosine is a membrane-targeted alkylphospholipid developed to inhibit the PI3K/Akt pathway and has been suggested as a favorable candidate for combined use with radiotherapy. In this study, we investigated the effect of the combined treatment of perifosine and radiation (CTPR) on prostate cancer cells in vitro and on prostate cancer xenografts in vivo.Methods: Human prostate cancer cell line, CWR22RV1, was treated with perifosine, radiation, or CTPR. Clonogenic survival assays, sulforhodamine B cytotoxity assays and cell density assays were used to assess the effectiveness of each therapy in vitro. Measurements of apoptosis, cell cycle analysis by flow cytometry and Western blots were used to evaluate mechanisms of action in vitro. Tumor growth delay assays were used to evaluate radiation induced tumor responses in vivo.Results: In vitro, CTPR had greater inhibitory effects on prostate cancer cell viability and clonogenic survival than either perifosine or radiation treatment alone. A marked increase in prostate cancer cell apoptosis was noted in CTPR. Phosphorylation of AKT-T308 AKT and S473 were decreased when using perifosine treatment or CTPR. Cleaved caspase 3 was significantly increased in the CTPR group. In vivo, CTPR had greater inhibitory effects on the growth of xenografts when compared with perifosine or radiation treatment alone groups.Conclusions: Perifosine enhances prostate cancer radiosensitivity in vitro and in vivo. These data provide strong support for further development of this combination therapy in clinical studies. © 2011 Gao et al; licensee BioMed Central Ltd.

Loading The State Key Laboratory of Oncology in Southern China collaborators
Loading The State Key Laboratory of Oncology in Southern China collaborators